Breaking News, Collaborations & Alliances

Angiex Initiates Phase 1 Clinical Trial of AGX101

Partners with Abzena, an end-to-end integrated CDMO, to support the development, manufacture and supply of clinical trial material for the study.

Author Image

By: Charlie Sternberg

Associate Editor

Angiex, a developer of Nuclear-Delivered Antibody-Drug Conjugate (ND-ADC) therapies for solid cancers, has begun patient dosing for its Phase 1 clinical trial of AGX101, a first-in-class TM4SF1-directed Antibody-Drug Conjugate (ADC).   Angiex partnered with Abzena, an end-to-end integrated CDMO for complex biologics and bioconjugates, to support the development, manufacture and supply of clinical trial material for the study.   AGX101 is a TM4SF1-directed ADC that targets two compartments of...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters